RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation for loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of Related Party Transactions, in the format specified in the accounting standards for the half year ended September 30, 2022. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our Letters dated October 11, 2022, October 17, 2022 and October 18, 2022, we would like to inform you that transcript of the Results Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2022, held on Tuesday, October 18, 2022, at 3.30 p.m. IST. has been made available on the Company's website at: https://www.rpglifesciences.com/website/earnings_call.php Kindly take the same on record and disseminate appropriately. RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation for loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record.
Results Earnings Call for Q2FY23 of RPG Life Sciences
Conference Call with RPG Life Sciences Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In continuation of our Letters dated October 11, 2022 and October 17, 2022, we would like to inform you that audio recording of the Results Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2022, held today i.e. Tuesday, October 18, 2022, at 3.30 p.m. IST. has been made available on the Company's website at https://www.rpglifesciences.com/website/earnings_call.php Kindly take the same on record and disseminate appropriately. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter and half year ended September 30, 2022. Kindly take this information on record. Q2FY23 Quarterly Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals company RPG Life Sciences announced Q2FY23 results: Q2FY23: RPG Life Sciences posted a jump in PBT by 21% YoY and by 8% QoQ EBITDA margins improved from 22.5% to 23.0% QoQ Revenue from operations at Rs 134.79 crores registered a growth of 20% YoY and a growth of 5% QoQ H1FY23: The company posted a jump in PBT by 25% YoY EBITDA margin expanded from 22.6% to 22.8% YoY Revenue from operations at Rs 263.72 crore registered a growth of 19% YoY Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2FY23, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 20% and 21% respectively YoY. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% QoQ. Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently ahead of market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has shown a robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations and eye on sales hygiene is helping us to consistently improve our margins. We are on course to implement our Transformation Agenda to achieve our strategic goals.” Result PDF RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation of our Letter dated October 11, 2022, please find enclosed herewith Investor Presentation for the quarter and half year ended September 30, 2022, for the Results Earnings Call scheduled on Tuesday, October 18, 2022, at 3.30 p.m. IST. Dial-in details of which are reproduced below for ready reference. Kindly take the same on record and disseminate appropriately. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022. Kindly take the above on record.